The monoclonal antibody pemivibart (Pemgarda, Invivyd) is well tolerated and appears effective in preventing symptomatic COVID-19 infection among patients with chronic lymphocytic leukemia (CLL), who can be severely immunocompromised, according to a study reported at MAD-ID 2025, in Orlando, Fla. (abstract 96E).
Authorized by the FDA under an emergency use authorization, pemivibart is indicated for certain patients with medical conditions or receiving immunosuppressive treatments leading to